Literature DB >> 27619539

A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson's disease.

Keita Matsuura1, Masayuki Maeda2, Ken-Ichi Tabei3, Maki Umino4, Hiroyuki Kajikawa5, Masayuki Satoh6, Hirotaka Kida6, Hidekazu Tomimoto7.   

Abstract

PURPOSE: Neuromelanin-sensitive MR imaging (NMI) is an increasingly powerful tool for the diagnosis of Parkinson's disease (PD). This study was undertaken to evaluate longitudinal changes on NMI in PD patients.
METHODS: We examined longitudinal changes on NMI in 14 PD patients. The area and contrast ratio (CR) of the substantia nigra pars compacta (SNc) were comparatively analyzed.
RESULTS: The total area and CR of the SNc upon follow-up NMI were significantly smaller than those on initial NMI (from 33.5±18.9 pixels and 6.35±2.86% to 21.5±16.7 pixels and 4.19±2.11%; Wilcoxon signed-rank test, p<0.001 and p=0.022, respectively). The area and CR of the dominant side SNc upon initial NMI were significantly greater than those on follow-up NMI (from 15.3±9.1 pixels and 6.5±2.7% to 7.9±8.5 pixels and 3.7±2.9%; Wilcoxon signed-rank test, p=0.002 and p=0.007, respectively). On a case-by-case basis, the area of the SNc invariably decreased upon follow-up NMI in all patients. We further demonstrated that the total area and CR of the SNc negatively correlated with disease duration (Pearson correlation coefficient, r=-0.63, p<0.001 and r=-0.41, p=0.031, respectively). In area analyses, our results demonstrated very high intraclass correlation coefficients for both intra- and inter-rater reliability.
CONCLUSION: NMI is a useful and reliable tool for detecting neuropathological changes over time in PD patients.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  3T magnetic resonance imaging; Longitudinal study; Neuromelanin-sensitive magnetic resonance imaging; Parkinson’s disease

Mesh:

Substances:

Year:  2016        PMID: 27619539     DOI: 10.1016/j.neulet.2016.09.011

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  21 in total

1.  The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis.

Authors:  Xiangming Wang; Yuehui Zhang; Chen Zhu; Guangzong Li; Jie Kang; Fang Chen; Ling Yang
Journal:  Neurol Sci       Date:  2019-08-07       Impact factor: 3.307

2.  Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease.

Authors:  Taku Hatano; Ayami Okuzumi; Koji Kamagata; Kensuke Daida; Daisuke Taniguchi; Masaaki Hori; Hiroyo Yoshino; Shigeki Aoki; Nobutaka Hattori
Journal:  J Neural Transm (Vienna)       Date:  2017-02-03       Impact factor: 3.575

Review 3.  Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review.

Authors:  Trina Mitchell; Stéphane Lehéricy; Shannon Y Chiu; Antonio P Strafella; A Jon Stoessl; David E Vaillancourt
Journal:  JAMA Neurol       Date:  2021-10-01       Impact factor: 29.907

4.  Longitudinal trimodal imaging of midbrain-associated network degeneration in Parkinson's disease.

Authors:  Kenan Steidel; Marina C Ruppert; David J Pedrosa; Carsten Eggers; Andrea Greuel; Masoud Tahmasian; Franziska Maier; Jochen Hammes; Thilo van Eimeren; Lars Timmermann; Marc Tittgemeyer; Alexander Drzezga
Journal:  NPJ Parkinsons Dis       Date:  2022-06-22

Review 5.  Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease.

Authors:  Jee-Young Lee; Antonio Martin-Bastida; Ane Murueta-Goyena; Iñigo Gabilondo; Nicolás Cuenca; Paola Piccini; Beomseok Jeon
Journal:  Nat Rev Neurol       Date:  2022-02-17       Impact factor: 44.711

Review 6.  Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.

Authors:  Jing Yang; Roxana G Burciu; David E Vaillancourt
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-02       Impact factor: 5.081

7.  Pool size ratio of the substantia nigra in Parkinson's disease derived from two different quantitative magnetization transfer approaches.

Authors:  Paula Trujillo; Paul E Summers; Alex K Smith; Seth A Smith; Luca T Mainardi; Sergio Cerutti; Daniel O Claassen; Antonella Costa
Journal:  Neuroradiology       Date:  2017-10-06       Impact factor: 2.804

Review 8.  MRI biomarkers of motor and non-motor symptoms in Parkinson's disease.

Authors:  Sephira G Ryman; Kathleen L Poston
Journal:  Parkinsonism Relat Disord       Date:  2019-10-10       Impact factor: 4.891

Review 9.  Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism.

Authors:  Nicola Pavese; Yen F Tai
Journal:  Mov Disord Clin Pract       Date:  2018-02-22

10.  Association between neuromelanin-sensitive MRI signal and psychomotor slowing in late-life depression.

Authors:  Guillermo Horga; Bret R Rutherford; Kenneth Wengler; Brandon K Ashinoff; Elena Pueraro; Clifford M Cassidy
Journal:  Neuropsychopharmacology       Date:  2020-09-12       Impact factor: 8.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.